Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder

Calciprotein particles (CPPs) are a new biological marker of chronic kidney disease-mineral and bone disorder (CKD-MBD). CPPs consist of phosphate, calcium, and some proteins, with phosphate being the major contributor to the level and biological activity of CPPs. Recent studies have shown the physi...

Full description

Saved in:
Bibliographic Details
Main Authors: Kenichi Akiyama, Takaaki Kimura, Kazuhiro Shiizaki
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2018/5282389
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849395329384841216
author Kenichi Akiyama
Takaaki Kimura
Kazuhiro Shiizaki
author_facet Kenichi Akiyama
Takaaki Kimura
Kazuhiro Shiizaki
author_sort Kenichi Akiyama
collection DOAJ
description Calciprotein particles (CPPs) are a new biological marker of chronic kidney disease-mineral and bone disorder (CKD-MBD). CPPs consist of phosphate, calcium, and some proteins, with phosphate being the major contributor to the level and biological activity of CPPs. Recent studies have shown the physiological and pathological significance of CPPs, including contributions to bone and mineral metabolism, and to tissue and organ impairments such as cardiovascular damage and inflammatory responses. These actions are well known as important aspects of CKD-MBD. Fibroblast growth factor 23 (FGF23), which is secreted from the bone as the phosphaturic hormone, is markedly elevated in CKD-MBD. Many clinical studies have shown significant relationships between the level of FGF23 and outcomes such as mortality, prevalence of cardiovascular disease, bone fracture, and levels of inflammatory markers. Basic and clinical studies have suggested that CPPs contribute to synthesis and secretion of FGF23. Surgical treatments such as renal transplantation and parathyroidectomy for patients with CKD-MBD suppress excess levels of phosphate, calcium, parathyroid hormone (PTH), and FGF23, which are related to the CPP level. Therefore, suppression of CPPs might also contribute to improved clinical outcomes after these treatments.
format Article
id doaj-art-aac4660c1b8a476d99a14cd718c7f23c
institution Kabale University
issn 1687-8337
1687-8345
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series International Journal of Endocrinology
spelling doaj-art-aac4660c1b8a476d99a14cd718c7f23c2025-08-20T03:39:40ZengWileyInternational Journal of Endocrinology1687-83371687-83452018-01-01201810.1155/2018/52823895282389Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone DisorderKenichi Akiyama0Takaaki Kimura1Kazuhiro Shiizaki2Division of Anti-Ageing Medicine, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi, JapanDivision of Renal Surgery and Transplantation, Department of Urology, Jichi Medical University, Shimotsuke, Tochigi, JapanDivision of Anti-Ageing Medicine, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi, JapanCalciprotein particles (CPPs) are a new biological marker of chronic kidney disease-mineral and bone disorder (CKD-MBD). CPPs consist of phosphate, calcium, and some proteins, with phosphate being the major contributor to the level and biological activity of CPPs. Recent studies have shown the physiological and pathological significance of CPPs, including contributions to bone and mineral metabolism, and to tissue and organ impairments such as cardiovascular damage and inflammatory responses. These actions are well known as important aspects of CKD-MBD. Fibroblast growth factor 23 (FGF23), which is secreted from the bone as the phosphaturic hormone, is markedly elevated in CKD-MBD. Many clinical studies have shown significant relationships between the level of FGF23 and outcomes such as mortality, prevalence of cardiovascular disease, bone fracture, and levels of inflammatory markers. Basic and clinical studies have suggested that CPPs contribute to synthesis and secretion of FGF23. Surgical treatments such as renal transplantation and parathyroidectomy for patients with CKD-MBD suppress excess levels of phosphate, calcium, parathyroid hormone (PTH), and FGF23, which are related to the CPP level. Therefore, suppression of CPPs might also contribute to improved clinical outcomes after these treatments.http://dx.doi.org/10.1155/2018/5282389
spellingShingle Kenichi Akiyama
Takaaki Kimura
Kazuhiro Shiizaki
Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder
International Journal of Endocrinology
title Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder
title_full Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder
title_fullStr Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder
title_full_unstemmed Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder
title_short Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder
title_sort biological and clinical effects of calciprotein particles on chronic kidney disease mineral and bone disorder
url http://dx.doi.org/10.1155/2018/5282389
work_keys_str_mv AT kenichiakiyama biologicalandclinicaleffectsofcalciproteinparticlesonchronickidneydiseasemineralandbonedisorder
AT takaakikimura biologicalandclinicaleffectsofcalciproteinparticlesonchronickidneydiseasemineralandbonedisorder
AT kazuhiroshiizaki biologicalandclinicaleffectsofcalciproteinparticlesonchronickidneydiseasemineralandbonedisorder